

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **VOLUNTARY ANNOUNCEMENT COOPERATION FRAMEWORK AGREEMENT**

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 9 November 2022 (after trading hours), the Company entered into a cooperation framework agreement (the “**Cooperation Framework Agreement**”) with Huashan Hospital affiliated to Fudan University, Shanghai\* (上海復旦大學附屬華山醫院) (“**Huashan Hospital**”), pursuant to which the parties agreed to strategically cooperate (the “**Cooperation**”) in various respects to promote the development of the boron neutron capture technology (“**BNCT**”) used in tumour treatment, thus providing higher quality medical services to cancer patients.

#### **THE COOPERATION FRAMEWORK AGREEMENT**

The principal terms of the Cooperation Framework Agreement are set out below:

**Date:** 9 November 2022

**Parties:** (i) Huashan Hospital; and

(ii) the Company

To the best of the Directors’ knowledge and information, having made all reasonable enquiries, Huashan Hospital and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

**Term:** Five (5) years from the date on which the Cooperation Framework Agreement is signed.

**Subject matter:** The parties agree to cooperate in academic exchange, technology transfer, clinical treatment and other respects in furtherance of their common aim to promote the BNCT tumor treatment technology in the People's Republic of China (the "**PRC**"). The parties specifically agree to cooperate on the following matters (among other matters):

- (1) Huashan Hospital agrees to provide professional guidance and advice as to the construction and operation of the BNCT treatment centre (the "**BNCT Centre**") in Hainan, the PRC, invested by the Company through Pengbo (Hainan) Medical Technology Company Limited\* (鹏博(海南)硼中子醫療科技有限公司), a company established under the laws of the PRC and an indirect wholly-owned subsidiary of the Company ("**Pengbo Hainan**"), with an aim to accelerate the construction of the BNCT Centre in Hainan and promote BNCT treatment in other parts of the PRC. Huashan Hospital also agrees that its experts may arrange for patients with advanced cancer to receive treatment at the BNCT Centre if considered appropriate;
- (2) the parties agree to jointly establish a BNCT research institute at the BNCT Centre at Lecheng, Pengbo, Hainan, the PRC, for carrying out academic exchange and scientific research on the BNCT project, training clinical talents, implementing technology transfer and application and making joint publications on the research. The Company agrees to provide funds for scientific research and for the construction and development of the said BNCT research institute;
- (3) the parties agree to accelerate cooperation in clinical studies and results application with an aim to obtain regulatory approval for new indications; and
- (4) the parties also agree to explore potential collaborative opportunities to establish a BNCT research centre in Shanghai, the PRC.

**Non-legally binding effect:**

The Cooperation Framework Agreement does not constitute a legally binding commitment or obligation on the parties in respect of the Cooperation. Specific and detailed terms of the Cooperation will be set forth in the definitive agreement(s) which may be entered into between the Company and Huashan Hospital, if any.

**REASONS FOR AND BENEFITS OF ENTERING INTO THE COOPERATION FRAMEWORK AGREEMENT**

Huashan Hospital is a hospital affiliated with the National Health Commission of the People's Republic of China (中華人民共和國國家衛生健康委員會) (the “**National Health Commission**”), Fudan University, and the Red Cross Society of China with leading medical technology and talent. It is one of the first hospitals in the PRC to have passed the national tertiary first-class hospital accreditation, one of the most prominent and internationalised medical education and research centres in the PRC, and one of the first pilot hospitals announced by the National Health Commission for multidisciplinary cancer treatment.

The Board believes that the formation of the strategic partnership with Huashan Hospital through the Cooperation Framework Agreement and the Cooperation will be beneficial to the development of the Group's business in the provision of BNCT treatment services through Pengbo Hainan and in turn maximise return to the Company and its shareholders in the long run.

**GENERAL**

The Board wishes to emphasise that while the Cooperation Framework Agreement forms the basis for the long-term strategic cooperation between the Company and Huashan Hospital, the entering into of any definitive cooperation agreement(s) is subject to further negotiations between the parties. The Board wishes to remind its shareholders that there is no assurance that any definitive cooperation agreement(s) will be signed between the parties concerned. The Cooperation or any transactions contemplated under the definitive cooperation agreement(s), if materialise, may or may not constitute notifiable transactions for the Company under Chapter 19 of the GEM Listing Rules. Further announcement(s) will be made by the Company to comply with the applicable requirements under the GEM Listing Rules as and when necessary.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 9 November 2022

*As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun and Mr. Huang Song; one non-executive Director, namely, Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*

\* *for identification purpose only*